The Metabolic Syndrome as a Risk Factor for Venous and Arterial Thrombosis

 

 Buy Article Permissions and Reprints

ABSTRACT

The metabolic syndrome is a cluster of risk factors for atherosclerosis. Although a universally accepted definition is still lacking because available classifications present slightly different diagnostic criteria, the metabolic syndrome is now recognized as a serious public health problem that affects up to 45% of the population >50 years of age in the United States and ~20 to 25% of the adult population in Europe.

To diagnose the metabolic syndrome, the concomitant presence of at least three components, among them visceral obesity defined by the measurement of the waist circumference, elevated blood pressure, hyperglycemia, hypertriglyceridemia, or reduced high-density lipoprotein cholesterol levels, is required.

The concomitant presence of these risk factors, and thus the presence of the metabolic syndrome, is associated with inflammatory and hypercoagulable states that through increased levels of coagulation factors, reduction in fibrinolysis, endothelial dysfunction, and platelet hyperreactivity may predispose patients to develop cardiovascular events.

Several studies have consistently shown that patients with the metabolic syndrome are at significantly increased risk of diabetes, coronary artery disease, and ischemic stroke. A few recent studies suggest that the metabolic syndrome may also play a role in the pathogenesis of venous thromboembolism, but this latter finding needs confirmation by large clinical studies.

REFERENCES

• 1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA. 2001;  285(19) 2486-2497
  CrossrefPubMedGoogle Scholar
• 2 Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1988;  37(12) 1595-1607
  CrossrefPubMedGoogle Scholar
• 3 Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.  Diabet Med. 1998;  15(7) 539-553
  CrossrefPubMedGoogle Scholar
• 4 Alberti K G, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group . The metabolic syndrome—a new worldwide definition.  Lancet. 2005;  366(9491) 1059-1062
  CrossrefPubMedGoogle Scholar
• 5 Grundy S M, Cleeman J I, Daniels S R American Heart Association et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.  Circulation. 2005;  112(17) 2735-2752
  CrossrefPubMedGoogle Scholar
• 6 Park Y W, Zhu S, Palaniappan L, Heshka S, Carnethon M R, Heymsfield S B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994.  Arch Intern Med. 2003;  163(4) 427-436
  CrossrefPubMedGoogle Scholar
• 7 Lakka H M, Laaksonen D E, Lakka T A et al.. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.  JAMA. 2002;  288(21) 2709-2716
  CrossrefPubMedGoogle Scholar
• 8 Balkau B, Charles M A, Drivsholm T European Group for the Study of Insulin Resistance (EGIR) et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome.  Diabetes Metab. 2002;  28(5) 364-376
  PubMedGoogle Scholar
• 9 Dallongeville J, Cottel D, Ferrières J et al.. Household income is associated with the risk of metabolic syndrome in a sex-specific manner.  Diabetes Care. 2005;  28(2) 409-415
  CrossrefPubMedGoogle Scholar
• 10 Bataille V, Perret B, Dallongeville J et al.. Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. A nested case-control study from the PRIME cohort.  Diabetes Metab. 2006;  32(5 Pt 1) 475-479
  CrossrefPubMedGoogle Scholar
• 11 Assmann G, Guerra R, Fox G et al.. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations.  Am J Cardiol. 2007;  99(4) 541-548
  CrossrefPubMedGoogle Scholar
• 12 Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults—a population study using modified ATP III criteria.  Diabetes Res Clin Pract. 2003;  60(3) 199-204
  CrossrefPubMedGoogle Scholar
• 13 Ko G T, Cockram C S, Chow C C et al.. High prevalence of metabolic syndrome in Hong Kong Chinese—comparison of three diagnostic criteria.  Diabetes Res Clin Pract. 2005;  69(2) 160-168
  CrossrefPubMedGoogle Scholar
• 14 Arai H, Yamamoto A, Matsuzawa Y et al.. Prevalence of metabolic syndrome in the general Japanese population in 2000.  J Atheroscler Thromb. 2006;  13(4) 202-208
  PubMedGoogle Scholar
• 15 Ford E S, Giles W H, Mokdad A H. Increasing prevalence of the metabolic syndrome among U.S. adults.  Diabetes Care. 2004;  27(10) 2444-2449
  CrossrefPubMedGoogle Scholar
• 16 Flegal K M, Carroll M D, Ogden C L, Johnson C L. Prevalence and trends in obesity among US adults, 1999–2000.  JAMA. 2002;  288(14) 1723-1727
  CrossrefPubMedGoogle Scholar
• 17 Alexander C M, Landsman P B, Grundy S M. The influence of age and body mass index on the metabolic syndrome and its components.  Diabetes Obes Metab. 2008;  10(3) 246-250
  CrossrefPubMedGoogle Scholar
• 18 Goodman E, Dolan L M, Morrison J A, Daniels S R. Factor analysis of clustered cardiovascular risks in adolescence: obesity is the predominant correlate of risk among youth.  Circulation. 2005;  111(15) 1970-1977
  CrossrefPubMedGoogle Scholar
• 19 Daniels S R, Arnett D K, Eckel R H et al.. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment.  Circulation. 2005;  111(15) 1999-2012
  CrossrefPubMedGoogle Scholar
• 20 Raynaud E, Pérez-Martin A, Brun J, Aïssa-Benhaddad A, Fédou C, Mercier J. Relationships between fibrinogen and insulin resistance.  Atherosclerosis. 2000;  150(2) 365-370
  CrossrefPubMedGoogle Scholar
• 21 Ford E S. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey.  Atherosclerosis. 2003;  168(2) 351-358
  CrossrefPubMedGoogle Scholar
• 22 Yudkin J S, Juhan-Vague I, Hawe E The HIFMECH Study Group et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study.  Metabolism. 2004;  53(7) 852-857
  CrossrefPubMedGoogle Scholar
• 23 Duncan B B, Schmidt M I, Chambless L E, Folsom A R, Carpenter M, Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults—the ARIC study. Atherosclerosis Risk in Communities.  Obes Res. 2000;  8 279-286
  CrossrefPubMedGoogle Scholar
• 24 Carvalho de Sousa J, Bruckert E, Giral P et al.. Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity.  Haemostasis. 1989;  19(3) 125-130
  PubMedGoogle Scholar
• 25 Grant P J. Diabetes mellitus as a prothrombotic condition.  J Intern Med. 2007;  262(2) 157-172
  CrossrefPubMedGoogle Scholar
• 26 Mineo C, Deguchi H, Griffin J H, Shaul P W. Endothelial and antithrombotic actions of HDL.  Circ Res. 2006;  98(11) 1352-1364
  CrossrefPubMedGoogle Scholar
• 27 Shimomura I, Funahashi T, Takahashi M et al.. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.  Nat Med. 1996;  2(7) 800-803
  CrossrefPubMedGoogle Scholar
• 28 Alessi M C, Bastelica D, Mavri A et al.. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.  Arterioscler Thromb Vasc Biol. 2003;  23(7) 1262-1268
  CrossrefPubMedGoogle Scholar
• 29 Marchesini G, Brizi M, Morselli-Labate A M et al.. Association of nonalcoholic fatty liver disease with insulin resistance.  Am J Med. 1999;  107(5) 450-455
  Google Scholar
• 30 Banfi C, Mussoni L, Risé P et al.. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells.  Circ Res. 1999;  85(2) 208-217
  PubMedGoogle Scholar
• 31 Festa A, Williams K, Tracy R P, Wagenknecht L E, Haffner S M. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.  Circulation. 2006;  113(14) 1753-1759
  CrossrefPubMedGoogle Scholar
• 32 Ingelsson E, Pencina M J, Tofler G H et al.. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study.  Circulation. 2007;  116(9) 984-992
  CrossrefPubMedGoogle Scholar
• 33 Godsland I F, Crook D, Proudler A J, Stevenson J C. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome.  J Clin Endocrinol Metab. 2005;  90(1) 190-197
  PubMedGoogle Scholar
• 34 Trovati M, Mularoni E M, Burzacca S et al.. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients.  Diabetes. 1995;  44(11) 1318-1322
  CrossrefPubMedGoogle Scholar
• 35 Ferreira I A, Mocking A I, Feijge M A et al.. Platelet inhibition by insulin is absent in type 2 diabetes mellitus.  Arterioscler Thromb Vasc Biol. 2006;  26(2) 417-422
  PubMedGoogle Scholar
• 36 Doggen C J, Smith N L, Lemaitre R N, Heckbert S R, Rosendaal F R, Psaty B M. Serum lipid levels and the risk of venous thrombosis.  Arterioscler Thromb Vasc Biol. 2004;  24(10) 1970-1975
  CrossrefPubMedGoogle Scholar
• 37 Englyst N A, Taube J M, Aitman T J, Baglin T P, Byrne C D. A novel role for CD36 in VLDL-enhanced platelet activation.  Diabetes. 2003;  52(5) 1248-1255
  CrossrefPubMedGoogle Scholar
• 38 Jarvis G E, Atkinson B T, Snell D C, Watson S P. Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens.  Br J Pharmacol. 2002;  137(1) 107-117
  CrossrefPubMedGoogle Scholar
• 39 Lyon C J, Law R E, Hsueh W A. Minireview: adiposity, inflammation, and atherogenesis.  Endocrinology. 2003;  144(6) 2195-2200
  CrossrefPubMedGoogle Scholar
• 40 Haffner S M, Miettinen H, Mykkänen L, Karhapää P, Rainwater D L, Laakso M. Leptin concentrations and insulin sensitivity in normoglycemic men.  Int J Obes Relat Metab Disord. 1997;  21(5) 393-399
  CrossrefPubMedGoogle Scholar
• 41 Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor.  Diabetes. 1999;  48(2) 426-429
  CrossrefPubMedGoogle Scholar
• 42 Ozata M, Avcu F, Durmus O, Yilmaz I, Ozdemir I C, Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency.  Obes Res. 2001;  9(10) 627-630
  CrossrefPubMedGoogle Scholar
• 43 Blake G J, Ridker P M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes.  J Am Coll Cardiol. 2003;  41(4 suppl S) 37S-42S
  CrossrefPubMedGoogle Scholar
• 44 Nickenig G. Should angiotensin II receptor blockers and statins be combined?.  Circulation. 2004;  110(8) 1013-1020
  CrossrefPubMedGoogle Scholar
• 45 Yamauchi T, Kamon J, Waki H et al.. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.  Nat Med. 2001;  7(8) 941-946
  CrossrefPubMedGoogle Scholar
• 46 Chen H, Montagnani M, Funahashi T, Shimomura I, Quon M J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells.  J Biol Chem. 2003;  278(45) 45021-45026
  CrossrefPubMedGoogle Scholar
• 47 Ouchi N, Kihara S, Funahashi T et al.. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.  Circulation. 2003;  107(5) 671-674
  CrossrefPubMedGoogle Scholar
• 48 Kato H, Kashiwagi H, Shiraga M et al.. Adiponectin acts as an endogenous antithrombotic factor.  Arterioscler Thromb Vasc Biol. 2006;  26(1) 224-230
  CrossrefPubMedGoogle Scholar
• 49 Elbatarny H S, Netherton S J, Ovens J D, Ferguson A V, Maurice D H. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases.  Eur J Pharmacol. 2007;  558(1-3) 7-13
  CrossrefPubMedGoogle Scholar
• 50 Thomas G N, Chook P, Qiao M et al.. Deleterious impact of “high normal” glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study.  Arterioscler Thromb Vasc Biol. 2004;  24(4) 739-743
  CrossrefPubMedGoogle Scholar
• 51 Kim J A, Montagnani M, Koh K K, Quon M J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.  Circulation. 2006;  113(15) 1888-1904
  CrossrefPubMedGoogle Scholar
• 52 Montagnani M, Golovchenko I, Kim I et al.. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells.  J Biol Chem. 2002;  277(3) 1794-1799
  CrossrefPubMedGoogle Scholar
• 53 McNeill A M, Rosamond W D, Girman C J et al.. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.  Diabetes Care. 2005;  28(2) 385-390
  CrossrefPubMedGoogle Scholar
• 54 Gami A S, Witt B J, Howard D E et al.. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies.  J Am Coll Cardiol. 2007;  49(4) 403-414
  CrossrefPubMedGoogle Scholar
• 55 Schillaci G, Pirro M, Vaudo G et al.. Prognostic value of the metabolic syndrome in essential hypertension.  J Am Coll Cardiol. 2004;  43(10) 1817-1822
  CrossrefPubMedGoogle Scholar
• 56 Tong P C, Kong A P, So W Y et al.. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program’s Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes.  Diabetes Care. 2007;  30(5) 1206-1211
  CrossrefPubMedGoogle Scholar
• 57 McNeill A M, Katz R, Girman C J et al.. Metabolic syndrome and cardiovascular disease in older people: the cardiovascular health study.  J Am Geriatr Soc. 2006;  54(9) 1317-1324
  CrossrefPubMedGoogle Scholar
• 58 Milionis H J, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis D P, Elisaf M S. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects.  Stroke. 2005;  36(7) 1372-1376
  CrossrefPubMedGoogle Scholar
• 59 Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease.  Stroke. 2005;  36(7) 1366-1371
  CrossrefPubMedGoogle Scholar
• 60 Kurl S, Laukkanen J A, Niskanen L et al.. Metabolic syndrome and the risk of stroke in middle-aged men.  Stroke. 2006;  37(3) 806-811
  CrossrefPubMedGoogle Scholar
• 61 Ageno W, Prandoni P, Romualdi E et al.. The metabolic syndrome and the risk of venous thrombosis: a case-control study.  J Thromb Haemost. 2006;  4(9) 1914-1918
  CrossrefPubMedGoogle Scholar
• 62 Ambrosetti M, Ageno W, Salerno M, Pedretti R F, Salerno-Uriarte J A. Metabolic syndrome as a risk factor for deep vein thrombosis after acute cardiac conditions.  Thromb Res. 2007;  120(6) 815-818
  CrossrefPubMedGoogle Scholar
• 63 Ay C, Tengler T, Vormittag R et al.. Venous thromboembolism—a manifestation of the metabolic syndrome.  Haematologica. 2007;  92(3) 374-380
  CrossrefPubMedGoogle Scholar
• 64 Ray J G, Lonn E, Yi Q HOPE-2 investigators et al. Venous thromboembolism in association with features of the metabolic syndrome.  QJM. 2007;  100(11) 679-684
  CrossrefPubMedGoogle Scholar
• 65 Prandoni P, Bilora F, Marchiori A et al.. An association between atherosclerosis and venous thrombosis.  N Engl J Med. 2003;  348(15) 1435-1441
  CrossrefPubMedGoogle Scholar
• 66 Becattini C, Agnelli G, Prandoni P et al.. A prospective study on cardiovascular events after acute pulmonary embolism.  Eur Heart J. 2005;  26(1) 77-83
  PubMedGoogle Scholar
• 67 Prandoni P, Ghirarduzzi A, Prins M H et al.. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis.  J Thromb Haemost. 2006;  4(9) 1891-1896
  CrossrefPubMedGoogle Scholar
• 68 Hansson P O, Eriksson H, Welin L, Svärdsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: “the study of men born in 1913”.  Arch Intern Med. 1999;  159(16) 1886-1890
  CrossrefPubMedGoogle Scholar
• 69 Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.  Arch Intern Med. 2000;  160(22) 3415-3420
  CrossrefPubMedGoogle Scholar
• 70 Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis.  Circulation. 2008;  117(1) 93-102
  CrossrefPubMedGoogle Scholar
• 71 Ray J G, Mamdani M, Tsuyuki R T, Anderson D R, Yeo E L, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis.  Arch Intern Med. 2001;  161(11) 1405-1410
  CrossrefPubMedGoogle Scholar
• 72 Ramcharan A S, Van Stralen K J, Snoep J D, Mantel-Teeuwisse A K, Rosendaal F R, Doggen C J. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis.  J Thromb Haemost. 2009;  7(4) 514-520
  CrossrefPubMedGoogle Scholar

Walter AgenoM.D. U.O. 

Medicina I, Ospedale di Circolo

Viale Borri 57, 21100 Varese, Italy

Email: agewal@yahoo.com